Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart cancer therapy: tailoring lung cancer treatment with a simple blood test

NCT ID NCT07709585

Not yet recruiting Disease control Sponsor: Guangzhou University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). Those with MRD receive added chemotherapy, while those without continue on befotertinib alone. The goal is to see if this adaptive strategy improves outcomes by giving more intensive treatment only when needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
befotertinib (a targeted cancer pill) plus pemetrexed and platinum chemotherapy
What this could lead to
If successful, this approach could offer a more personalized treatment plan for people with EGFR-mutant lung cancer, potentially improving how long they live without their cancer growing.
What could go wrong
This is an early-phase trial with only 124 participants, so results may not apply to everyone. The MRD-guided strategy is experimental, and adding chemotherapy increases side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) EGFR EXON 19 DELETION MUTATION EGFR EXON 21 L858R MUTATION EGFR EXON 21 MUTATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial Hospital of Chinese Medicine

    Guangzhou, Guangdong, 510120, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.